Zoledronic acid, pravastatin ( DrugBank: Pravastatin, Zoledronic acid )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
333ハッチンソン・ギルフォード症候群3

333. ハッチンソン・ギルフォード症候群


臨床試験数 : 8 薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00916747
(ClinicalTrials.gov)
August 20095/6/2009Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaAn Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid LaminopathiesProgeriaDrug: Lonafarnib, Zoledronic Acid, and PravastatinBoston Children's HospitalSchering-Plough;Merck Sharp & Dohme LLC;Eiger BioPharmaceuticalsActive, not recruitingN/AN/AAll85Phase 2United States
2NCT00879034
(ClinicalTrials.gov)
March 20098/4/2009A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaA Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: Lonafarnib;Drug: Zoledronic Acid;Drug: PravastatinBoston Children's HospitalDana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-PloughCompletedN/AN/AAll5Phase 2United States
3NCT00731016
(ClinicalTrials.gov)
October 20081/8/2008Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic AcidTreatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic AcidHutchinson-Gilford Progeria SyndromeDrug: Zoledronic acid, pravastatinAssistance Publique Hopitaux De MarseilleNULLCompleted3 YearsN/ABoth15Phase 2France